[go: up one dir, main page]

WO2025199211A1 - Imidazopyridines et imidazopyrimidines, et leurs procédés d'utilisation - Google Patents

Imidazopyridines et imidazopyrimidines, et leurs procédés d'utilisation

Info

Publication number
WO2025199211A1
WO2025199211A1 PCT/US2025/020532 US2025020532W WO2025199211A1 WO 2025199211 A1 WO2025199211 A1 WO 2025199211A1 US 2025020532 W US2025020532 W US 2025020532W WO 2025199211 A1 WO2025199211 A1 WO 2025199211A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
certain embodiments
subject
attorney docket
disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/020532
Other languages
English (en)
Inventor
Mark Fields
Denton HOYER
Lician DEL PRIORE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of WO2025199211A1 publication Critical patent/WO2025199211A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • retinitis pigmentosa (RP) which is known to be caused by around 200 different gene defects; choroideremia; retinal ganglion cell atrophy in glaucoma; and age-related macular degeneration (AMD), which is the leading cause of blindness in elderly patients.
  • RP retinitis pigmentosa
  • AMD age-related macular degeneration
  • AMD age-related macular degeneration
  • the retinal pigment epithelial (RPE) cells are vital for a proper functioning neurosensory retina.
  • the cells make up a portion of the RPE-Bruch’s membrane-choroid complex and perform critical functions for maintaining vision, including phagocytosis of photoreceptor outer segments, processing of retinoids, and polarized secretion of factors such as vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF).
  • VEGF vascular endothelial growth factor
  • PEDF pigment epithelium-derived factor
  • Age-related changes in RPE cells are a hallmark of early AMD and contribute to pathology and visual morbidity associated with advanced AMD. Oxidative stress is a contributing factor to these changes and has been implicated in other diseases in which aging is a risk factor, including Alzheimer’s disease and Parkinson’s disease.
  • Mendelian disorders such as most forms of RP
  • oxidative stress can accelerate cone photoreceptor death in animal models of RP.
  • Attorney Docket No.047162-7485WO1(02576) and ocular surface disease (dry eye) are leading causes of blindness and virtual impairment worldwide.
  • Oxidative stress, inflammation, and mitochondrial dysfunction have been implicated in these anterior segment diseases, including but not limited to Fuchs endothelial corneal dystrophy (FECD), ocular surface disease, cataracts, glaucoma, and keratoconus.
  • FECD Fuchs endothelial corneal dystrophy
  • Age-related changes in cornea endothelial cells are a hallmark of FECD and contribute to pathology and visual morbidity.
  • FECD is a progressive, bilateral disease characterized by a gradual loss of corneal endothelial cells (CECs). Loss of CECs impairs the ability of the cornea to maintain hydration, and results in a progressive decline in corneal transparency and hence a decline in vision.
  • CECs corneal endothelial cells
  • CECs are a highly metabolic cell type, exposure to sunlight and the lack of a significant capacity for natural regeneration of CECs make them susceptible to mitochondrial dysfunction and oxidative damage.
  • Increased oxidative stress in the FECD cornea contributes to endothelial oxidative DNA damage, morphological modification, and CEC apoptosis.
  • Age-related cataracts are a leading cause of loss of vision among elderly individuals affecting approximately 46% of 180 million visually disabled people worldwide.
  • Age-related changes in lens epithelial cells are a hallmark of cataract formation and contributes to pathology and visual morbidity.
  • Increased oxidative stress is caused by factors such as ultraviolet light and hydrogen peroxide, and both are risk factors for cataract development.
  • IOL intraocular lens
  • this surgery carries some inherent risks of post-operative complications such as stimulation of chronic inflammation, cystoid macular edema, corneal edema, endophthalmitis, retinal detachment, vitreous hemorrhage, and other disorders.
  • inadequate surgical facilities and the high cost of artificial IOLs can be major limitations to treatment in developing countries.
  • Keratoconus is a leading cause of corneal transplantation in younger individuals, accounting for approximately 25% of all transplants.
  • Chronic keratocyte apoptosis, particularly of the anterior stromal keratocytes can lead to stromal thinning in keratoconus.
  • Oxidative stress is one of the key factors that contributes to keratoconus pathogenesis. Oxidative stress, including oxidative damage to trabecular meshwork cells, has been implicated in the pathogenesis of glaucoma and/or ocular surface disease. There is a statistically significant correlation between oxidative DNA damage and daily mean, minimum, and maximum intraocular pressure (IOP) values. Thus, there is a need for early interventions that protect or rescue RPE cells. As such -2- 55240579.2 Attorney Docket No.047162-7485WO1(02576) an intervention would be beneficial and treat, ameliorate, and/or prevent disease progression.
  • IOP intraocular pressure
  • compositions and methods for treating, ameliorating, and/or preventing anterior segment disorders such as but not limited to FECD, cataracts, ocular surface disease, glaucoma, and/or keratoconus.
  • anterior segment disorders such as but not limited to FECD, cataracts, ocular surface disease, glaucoma, and/or keratoconus.
  • GA geographic atrophy
  • X 1 is N or CR 1 ; selected from the group consisting of H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , CH(CH 3 ) 2 , F, Cl, Br, I, and Y, with the proviso that at least one of R 1 (if present), R 2 , R 3 , and R 4 is Y; Y is -(CH2)m-G; m is 1, 2, 3, 4, 5, or 6; G is selected from the group consisting ; n is 0, 1, 2, 3, or 4; one of the following applies: X 2 is CR 7 , X 3 is CR 8 , and X 4 is CR 13 , or X 2 is N, X 3 is CR 8 , and X 4 is CR 13 , or X 2 is CR 7 , X 3 is N, and X 4 is CR 13 , or X 2 is CR 7 , or X 2 is CR 7 , or X 3 is N, and X 4 is CR 13
  • described herein is a method of treating, ameliorating, and/or preventing retinal degeneration in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound as described herein. -3- 55240579.2 Attorney Docket No.047162-7485WO1(02576)
  • described herein is a method of treating, ameliorating, and/or preventing cell death, and/or promoting cell viability, in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound as described herein.
  • described herein is a method of treating, ameliorating, and/or preventing blue light damage in a subject’s lens epithelial cell, the method comprising administering to the subject a therapeutically effective amount of a compound as described herein.
  • a pharmaceutical composition comprising a compound as described herein and at least one pharmaceutically acceptable excipient.
  • FIG.1 shows DH464A protects human retinal pigment epithelial (RPE) cells from oxidative stress-induced cell death.
  • RPE retinal pigment epithelial
  • Human RPE cells were preincubated with 3 ⁇ M or 6 ⁇ M DH464A for 24 hours and then exposed to 300 ⁇ M tert-butyl hydroperoxide (TBHP) to induce cell death for 24 hours.
  • TBHP tert-butyl hydroperoxide
  • EC 50 2.09 ⁇ M.
  • FIG.2 shows DH404AF and DH476A protect human retinal pigment epithelial (RPE) cells from oxidative stress-induced cell death.
  • FIG.3 shows structure activity relationship studies for imidazopyrimidines and pyridines. Imidazopyrimidines and pyridine 5,6 core compounds active after exposure to tert- butyl hydroperoxide-induced ferroptotic cell death. Data suggest binding to a biological enzyme or receptor.
  • FIG.4 shows prevention of RSL3-induced ferroptosis by GPX4 activator DH464A in ARPE-19 cells.
  • DH464A prevented cell death with a lethal concentration of RSL3 (10 nM).
  • -4- 55240579.2 Attorney Docket No.047162-7485WO1(02576) Human RPE cells were preincubated with 10 nM RSL3 alone or RSL3 + 10 nM compound C325-0414 for 24 hours and then analyzed with viability assay. ****p ⁇ 0.001.
  • FIG.6 shows the predicted binding mode of DH464A.
  • FIG.7 shows surface plasmon resonance (SPR) experiments using DH476A for GPX4 target identification.
  • Compound was tested using Cayman GPX4 (Cayman Chemical, Ann Arbor, MI; item number 26906).
  • the CM5 sensor Chip was used and GPX4 was immobilized using standard amine coupling.10 ⁇ g/ml GPX4 diluted in acetate buffer pH 4.5 was used.1x phosphate buffer saline (PBS-P; Cytiva Life Sciences; Marlborough, MA) was used as running buffer.
  • PBS-P phosphate buffer saline
  • FIG.8 shows surface plasmon resonance (SPR) experiments using DH404AF for GPX4 target identification.
  • Compound was tested using Cayman GPX4 (Cayman Chemical, Ann Arbor, MI; item number 26906).
  • the CM5 sensor Chip was used and GPX4 was immobilized using standard amine coupling.10 ⁇ g/ml GPX4 diluted in acetate buffer pH 4.5 was used.1x phosphate buffer saline (PBS-P; Cytiva Life Sciences; Marlborough, MA) was used as running buffer. Compounds were diluted to get 5% dimethyl sulfoxide (DMSO; Cytiva Life Sciences) in 1x PBS-P buffer. The compound was tested at the following concentrations ( ⁇ M): 0, 0.78, 1.56, 3.125, 6.25, 12.5, 25, 50, 100, 200, 400. The SPR curves and the fitted data to get dissociation constant (Kd) values for each channel are shown.
  • DMSO dimethyl sulfoxide
  • FIG.9 shows surface plasmon resonance (SPR) experiments using DH464A for -5- 55240579.2 Attorney Docket No.047162-7485WO1(02576) GPX4 target identification. Compound was tested using Cayman GPX4 (Cayman Chemical, Ann Arbor, MI; item number 26906). The CM5 sensor Chip was used and GPX4 was immobilized using standard amine coupling.10 ⁇ g/ml GPX4 diluted in acetate buffer pH 4.5 was used.1x phosphate buffer saline (PBS-P; Cytiva Life Sciences; Marlborough, MA) was used as running buffer.
  • PBS-P phosphate buffer saline
  • the acts can be carried out in any order, except when a temporal or operational sequence is explicitly recited.
  • specified acts can be carried out concurrently unless explicit claim language recites that they be carried out separately.
  • a claimed act of doing X and a claimed act of doing Y can be conducted simultaneously within a single operation, and the resulting process will fall within the literal scope of the claimed process.
  • values expressed in a range format should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited.
  • a range of “about 0.1% to about 5%” or “about 0.1% to 5%” should be interpreted to include not just about 0.1% to about 5%, but also the individual values (e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.1% to 0.5%, 1.1% to 2.2%, 3.3% to 4.4%) within the indicated range.
  • the statement “about X to Y” has the same meaning as “about X to about Y,” unless indicated otherwise.
  • the statement “about X, Y, or about Z” has the same meaning as “about X, about Y, or about Z,” unless indicated otherwise.
  • alkyl refers to straight chain and branched alkyl groups and cycloalkyl groups having from 1 to 40 carbon atoms, 1 to about 20 carbon atoms, 1 to 12 carbons or, in some embodiments, from 1 to 8 carbon atoms.
  • straight chain alkyl groups include those with from 1 to 8 carbon atoms such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups.
  • branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, t-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups.
  • alkyl encompasses n- alkyl, isoalkyl, and anteisoalkyl groups as well as other branched chain forms of alkyl.
  • Representative substituted alkyl groups can be substituted one or more times with any of the groups listed herein, for example, amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups.
  • alkenyl refers to straight and branched chain and cyclic alkyl groups as defined herein, except that at least one double bond exists between two carbon atoms.
  • alkenyl groups have from 2 to 40 carbon atoms, or 2 to about 20 carbon atoms, or 2 to 12 carbon atoms or, in some embodiments, from 2 to 8 carbon atoms.
  • a disease or disorder is “alleviated” if the severity of a symptom of the disease or disorder, the frequency with which such a symptom is experienced by a patient, or both, is reduced.
  • C325-0414 or “YU162779” refers to the compound 4-bromo-2- -7- 55240579.2 Attorney Docket No.047162-7485WO1(02576) (3-((2-ethyl-6-methylphenyl)amino)imidazo[1,2-a]pyrimidin-2-yl)phenol, or a salt and/or solvate thereof having the formula: .
  • the term composition refers to a mixture of at least one compound with a pharmaceutically acceptable carrier. The pharmaceutical composition facilitates administration of the compound to a patient or subject.
  • Compound 434 or “YU162787” refers to the compound 4- bromo-2-(3-((2-ethyl-6-methylphenyl)amino)-5,7-dimethylimidazo[1,2-a]pyrimidin-2- yl)phenol, or a salt and/or solvate thereof, having the formula: .
  • the term 4 corresponds to 4-bromo-2-(3- (pyridin-2-ylamino)imidazo[1,2-a]pyrimidin-2-yl)phenol, or a salt and/or solvate thereof, having the formula: HO N N Br .
  • a “disease” is a state the animal cannot maintain homeostasis, and wherein if then the animal’s health continues to deteriorate.
  • a “disorder” in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal’s state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal’s state of health.
  • the terms “effective amount,” “pharmaceutically effective amount” and “therapeutically effective amount” refer to a nontoxic but sufficient amount of an agent to provide the desired biological result.
  • Erastin refers to the compound 2-[1-[4-[2-(4- Chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4(3H)-quinazolinone, or a salt and/or solvate thereof, having the formula: .
  • X 1 , X 2 , and X 3 are independently selected from noble gases” would include the -9- 55240579.2 Attorney Docket No.047162-7485WO1(02576) scenario where, for example, X 1 , X 2 , and X 3 are all the same, where X 1 , X 2 , and X 3 are all different, where X 1 and X 2 are the same but X 3 is different, and other analogous permutations.
  • the terms “patient,” “subject,” “individual,” and the like are used interchangeably herein, and refer to any animal, or cells thereof whether in vitro or in situ, amenable to the methods described herein.
  • the patient, subject or individual is a human.
  • pharmaceutically acceptable refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively non-toxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
  • the term “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, substrate, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the disclosure within or to the patient such that it may perform its intended function.
  • a pharmaceutically acceptable material, composition or carrier such as a liquid or solid filler, stabilizer, dispersing agent, substrate, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the disclosure within or to the patient such that it may perform its intended function.
  • Such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body.
  • Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, including the compound useful within the disclosure, and not injurious to the patient.
  • materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline
  • “pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of the compound useful within the disclosure and are physiologically acceptable to the patient. -10- 55240579.2 Attorney Docket No.047162-7485WO1(02576) Supplementary active compounds may also be incorporated into the compositions.
  • the “pharmaceutically acceptable carrier” may further include a pharmaceutically acceptable salt of the compound useful within the disclosure.
  • Other additional ingredients that may be included in the pharmaceutical compositions used in the practice of the disclosure are known in the art and described, for example in Remington’s Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.
  • pharmaceutically acceptable salt refers to a salt of the administered compounds prepared from pharmaceutically acceptable non-toxic acids or bases, including inorganic acids or bases, organic acids or bases, solvates, hydrates, or clathrates thereof.
  • Suitable pharmaceutically acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid.
  • inorganic acids include hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric (including sulfate and hydrogen sulfate), and phosphoric acids (including hydrogen phosphate and dihydrogen phosphate).
  • Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, malonic, saccharin, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, trifluoromethanesulfonic, 2- hydroxyethanesulfonic, p-toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic,
  • Suitable pharmaceutically acceptable base addition salts of compounds described herein include, for example, ammonium salts, metallic salts including alkali metal, alkaline earth metal and transition metal salts such as, for example, calcium, magnesium, potassium, sodium and zinc salts.
  • Pharmaceutically acceptable base addition salts also include organic salts made from basic amines such as, for example, N,N’-dibenzylethylene-diamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared from the corresponding compound by reacting, for example, the appropriate acid or base with the compound.
  • RSL3 refers to the compound methyl (1S,3R)-2-(2-chloroacetyl)- 1-(4-(methoxycarbonyl)phenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate or a salt and/or solvate thereof, having the formula: -11- 55240579.2 Attorney Docket No.047162-7485WO1(02576) .
  • solvent as that can dissolve a solid, liquid, or gas. Non-limiting examples of are compounds, water, alcohols, ionic liquids, and supercritical fluids.
  • substantially refers to a majority of, or mostly, as in at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.99%, or at least about 99.999% or more, or 100%.
  • substantially free of can mean having none or having a trivial amount of, such that the amount of material present does not affect the material properties of the composition including the material, such that the composition is about 0 wt% to about 5 wt% of the material, or about 0 wt% to about 1 wt%, or about 5 wt% or less, or less than, equal to, or greater than about 4.5 wt%, 4, 3.5, 3, 2.5, 2, 1.5, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.01, or about 0.001 wt% or less.
  • substantially free of can mean having a trivial amount of, such that a composition is about 0 wt% to about 5 wt% of the material, or about 0 wt% to about 1 wt%, or about 5 wt% or less, or less than, equal to, or greater than about 4.5 wt%, 4, 3.5, 3, 2.5, 2, 1.5, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.01, or about 0.001 wt% or less, or about 0 wt%.
  • substituted or “functional group” as used herein refers to a group that can be or is substituted onto a molecule or onto an organic group.
  • substituents or functional groups include, but are not limited to, a halogen (e.g., F, Cl, Br, and I); an oxygen atom in groups such as hydroxy groups, alkoxy groups, aryloxy groups, aralkyloxy groups, oxo(carbonyl) groups, carboxyl groups including carboxylic acids, carboxylates, and carboxylate esters; a sulfur atom in groups such as thiol groups, alkyl and aryl sulfide groups, sulfoxide groups, sulfone groups, sulfonyl groups, and sulfonamide groups; a nitrogen atom in groups such as amines, hydroxyamines, nitriles, nitro groups, N-oxides, hydrazides, azides, and enamines; and other heteroatoms in various other groups.
  • a halogen e.g., F, Cl, Br, and I
  • an oxygen atom in groups such as hydroxy groups, al
  • Non-limiting examples of substituents that can be bonded to a substituted carbon (or other) atom include F, Cl, Br, I, OR, OC(O)N(R) 2 , CN, NO, NO 2 , ONO 2 , azido, CF 3 , OCF 3 , R, O (oxo), S (thiono), C(O), S(O), methylenedioxy, ethylenedioxy, N(R)2, SR, SOR, SO2R, SO2N(R)2, SO3R, C(O)R, -12- 55240579.2 Attorney Docket No.047162-7485WO1(02576) C(O)C(O)R, C(O)CH2C(O)R, C(S)R, C(O)OR, OC(O)R, C(O)N(R)2, OC(O)N(R)2, C(S)N(R) 2 , (CH 2 ) 0-2 N(R)C(O
  • substituted refers to the state in which one or more hydrogen atoms contained therein are replaced by one or more non-hydrogen atoms.
  • the substitution can be direct substitution, whereby the hydrogen atom is replaced by a functional group or substituent, or an indirect substitution, whereby an intervening linker group replaces the hydrogen atom, and the substituent or functional group is bonded to the intervening linker group.
  • direct substitution is: RR-H ⁇ RR-Cl, wherein RR is an organic moiety/fragment/molecule.
  • a example of indirect substitution is: RR-H ⁇ RR- (LL)zz-Cl, wherein RR is an organic moiety/fragment/molecule, LL is an linker group, and ‘zz’ is an integer from 0 to 100 inclusive. When zz is 0, LL is absent, and direct substitution results.
  • (LL) zz can be linear, branched, cyclic, acyclic, and combinations thereof.
  • a “therapeutic” treatment is a treatment administered to a subject who exhibits signs of pathology, for the purpose of diminishing or eliminating those signs.
  • ranges throughout this disclosure, various aspects of the disclosure can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, and so forth, as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6.
  • the disclosure provides compounds and methods for the treatment, prevention, and/or amelioration of retinal degeneration, including but not limited to AMD.
  • the disclosure provides compounds and methods for the treatment, prevention, and/or amelioration of anterior segment ocular disorders, such as but not limited to Fuchs endothelial corneal dystrophy (FECD), cataracts, ocular surface disease (dry eye), glaucoma, and/or keratoconus.
  • FECD Fuchs endothelial corneal dystrophy
  • cataracts cataracts
  • ocular surface disease dry eye
  • glaucoma glaucoma
  • keratoconus keratoconus
  • these compounds protect retinal cells, such as RPE cells, from cell death, in a non-limiting example oxidative stress-induced cell death.
  • these compounds protect retinal cells, such as RPE cells, from cell death on damaged extracellular matrix.
  • these compounds increase cell viability, wherein the cell is for example a lens epithelial cell.
  • these compounds protect retinal cells, such as RPE cells, from blue light damage.
  • Administration of compounds of the disclosure can induce expression of oxidative stress and anti-apoptotic related genes, thereby treating, ameliorating, and/or preventing retinal degenerations, including but not limited to AMD, including but not limited to “dry” AMD.
  • Oxidative stress is associated with a wide range of retinal degenerations, and oxidative stress has been shown to decrease photoreceptor/neuronal survival human diseases, including age-related macular degeneration (AMD), atherosclerosis, Alzheimer’s disease and others.
  • Oxidative stress is a general mechanism in which cells and tissues undergo damage in high oxygen environments. Mechanisms will vary depending on disease process, but include mitochondrial damage and dysfunction, peroxide production, free radical formation, and other mechanisms. Without loss of generality, drugs that prevent or reverse effects of tissue damage from oxidative stress are useful for slowing or reversing the progression of human disease.
  • Non-limiting examples of such diseases include heart failure and other cardiovascular such as atherosclerosis; retinal degenerations such as age- related macular degeneration; pulmonary fibrosis; kidney (renal) disease; diabetic macular edema and retinopathies; neurodegenerations such as Alzheimer’s disease; certain skeletal muscle disorders such as mitochondrial myopathy and Barth’s syndrome; ocular disorders -14- 55240579.2 Attorney Docket No.047162-7485WO1(02576) and diseases such as cataract and glaucoma; and liver disease.
  • exemplary compounds of the disclosure were found to mitigate risk of oxidative damage in tissue culture models of disease.
  • compounds of the disclosure were shown to protect human retinal pigment epithelial (RPE) cells from oxidative stress-induced cell death and are beneficial to treat, ameliorate, and/or prevent diseases contemplated herein.
  • compounds of the disclosure enhance metabolic function, such as adenosine triphosphate (ATP) production, basal respiration, maximal respiration, and/or spare respiration in RPE cells.
  • compounds of the disclosure have good solubility in aqueous buffers (from 1-20 mg/mL) and can be formulated for administration to any section of the eye of a subject in need thereof.
  • the compounds of the disclosure have a solubility of at least 0.1 mg/mL in an aqueous buffer and/or water, such as in an aqueous pharmaceutical composition suitable for ocular delivery. In some embodiments, the compounds of the disclosure have a solubility of at least 1 mg/mL in an aqueous buffer and/or water, such as in an aqueous pharmaceutical composition suitable for ocular delivery.
  • ROS reactive oxygen species
  • oxidative stress can lead to damage to retinal cells, including those in the macula.
  • Lipid peroxidation is a process in which reactive oxygen species attack and damage lipids (fatty acids) in cell membranes. This process can disrupt the integrity and function of retinal cells, including those in the macula, leading to cell death and the development of AMD.
  • GPX4 is an enzyme that helps protect cells from oxidative damage by reducing lipid peroxides, the harmful byproducts of lipid peroxidation.
  • GPX4 acts as a potent antioxidant enzyme that directly reduces lipid hydroperoxides, preventing their accumulation and subsequent oxidative damage.
  • GPX4 Converts lipid hydroperoxides into their corresponding alcohols, thereby -15- 55240579.2 Attorney Docket No.047162-7485WO1(02576) neutralizing their harmful effects.
  • This enzymatic activity of GPX4 is crucial in preventing ferroptosis. For instance, studies have shown that genetic or pharmacological inhibition of GPX4 leads to increased lipid peroxidation and subsequent ferroptotic cell death in various cell types. Iron plays a central role in ferroptosis, as it catalyzes the formation of lipid hydroperoxides through the Fenton reaction.
  • GPX4 activation is closely linked to iron metabolism, as it can sequester and utilize free iron ions to catalyze the reduction of lipid hydroperoxides. By efficiently utilizing iron, GPX4 prevents its accumulation and subsequent lipid peroxidation, thereby protecting cells from ferroptotic death. This interplay between GPX4 and iron metabolism highlights the importance of GPX4 activation in preventing ferroptosis. In addition to its direct antioxidant activity, GPX4 also plays a crucial role in lipid repair. Lipid peroxidation can lead to the generation of highly reactive lipid species, such as 4-hydroxynonenal (4-HNE), which can further propagate oxidative damage.
  • 4-HNE 4-hydroxynonenal
  • GPX4 activation helps in the removal of these reactive lipid species, preventing their detrimental effects on cellular membranes.
  • This lipid repair function of GPX4 is essential for maintaining membrane integrity and preventing ferroptotic cell death.
  • the activation of GPX4 is a critical factor in preventing ferroptotic cell death. Through its antioxidant activity, GPX4 efficiently reduces lipid hydroperoxides, preventing their accumulation and subsequent oxidative damage. Moreover, GPX4's role in iron metabolism and lipid repair further emphasizes its significance in safeguarding cellular integrity.
  • the disclosure provides a compound of formula (I), or a salt, solvate, tautomer, and/or stereoisomer thereof (such as, but not limited to, a geometric isomer and/or enantiomer and/or diastereoisomer thereof): -16- 55240579.2 Attorney Docket No.047162-7485WO1(02576) (I), wherein: X 1 is N or CR 1 ; R 1 (if present), R 2 , R 3 , and R 4 are independently selected from the group consisting of H, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, F, Cl, Br, I, and Y, with the proviso that at least one of R 1 (if present), R 2 , R 3 , and R 4 is Y; Y is -(CH 2 ) m -G; m is 1, 2, 3, 4, 5, or 6; G is selected from the group consisting of: ; n is 0, 1, 2, 3, one
  • X 1 is N. In certain embodiments, X 1 is CR 1 . In certain embodiments, X 2 is CR 7 , X 3 is CR 8 , and X 4 is CR 13 . In certain embodiments, X 2 is N, X 3 is CR 7 , and X 4 is CR 8 . In certain embodiments, X 2 is CR 7 , X 3 is N, and X 4 is CR 8 . In certain embodiments, X 2 is CR 7 , X 3 is CR 8 , and X 4 is N. In certain embodiments, R 1 is H. In certain embodiments, R 1 is CH 3 . In certain embodiments, R 1 is CH2CH3.
  • R 1 is CH2CH2CH3. In certain embodiments, R 1 is CH(CH 3 ) 2 . In certain embodiments, R 1 is F. In certain embodiments, R 1 is Cl. In certain embodiments, R 1 is Br. In certain embodiments, R 1 is I. In certain embodiments, R 1 is Y. -17- 55240579.2 Attorney Docket No.047162-7485WO1(02576) In certain embodiments, R 2 is H. In certain embodiments, R 2 is CH3. In certain embodiments, R 2 is CH 2 CH 3 . In certain embodiments, R 2 is CH 2 CH 2 CH 3 . In certain embodiments, R 2 is CH(CH3)2. In certain embodiments, R 2 is F. In certain embodiments, R 2 is Cl.
  • R 2 is Br. In certain embodiments, R 2 is I. In certain embodiments, R 2 is Y. In certain embodiments, R 3 is H. In certain embodiments, R 3 is CH 3 . In certain embodiments, R 3 is CH2CH3. In certain embodiments, R 3 is CH2CH2CH3. In certain embodiments, R 3 is CH(CH 3 ) 2 . In certain embodiments, R 3 is F. In certain embodiments, R 3 is Cl. In certain embodiments, R 3 is Br. In certain embodiments, R 3 is I. In certain embodiments, R 3 is Y. In certain embodiments, R 4 is H. In certain embodiments, R 4 is CH3. In certain embodiments, R 4 is CH 2 CH 3 .
  • R 4 is CH 2 CH 2 CH 3 . In certain embodiments, R 4 is CH(CH3)2. In certain embodiments, R 4 is F. In certain embodiments, R 4 is Cl. In certain embodiments, R 4 is Br. In certain embodiments, R 4 is I. In certain embodiments, R 4 is Y. In certain embodiments, R 5 is H. In certain embodiments, R 5 is CH3. In certain embodiments, R 5 is CH2CH3. In certain embodiments, R 5 is CH2CH2CH3. In certain embodiments, R 5 is CH(CH3)2. In certain embodiments, R 5 is F. In certain embodiments, R 5 is Cl. In certain embodiments, R 5 is Br. In certain embodiments, R 5 is I. In certain embodiments, R 6 is H.
  • R 6 is CH3. In certain embodiments, R 6 is CH 2 CH 3 . In certain embodiments, R 6 is CH 2 CH 2 CH 3 . In certain embodiments, R 6 is CH(CH3)2. In certain embodiments, R 6 is F. In certain embodiments, R 6 is Cl. In certain embodiments, R 6 is Br. In certain embodiments, R 6 is I. In certain embodiments, R 7 is H. In certain embodiments, R 7 is CH3. In certain embodiments, R 7 is CH 2 CH 3 . In certain embodiments, R 7 is CH 2 CH 2 CH 3 . In certain embodiments, R 7 is CH(CH3)2. In certain embodiments, R 7 is F. In certain embodiments, R 7 is Cl. In certain embodiments, R 7 is Br.
  • R 7 is I.
  • R 8 is H. In certain embodiments, R 8 is CH3. In certain embodiments, R 8 is CH 2 CH 3 . In certain embodiments, R 8 is CH 2 CH 2 CH 3 . In certain embodiments, R 8 is CH(CH3)2. In certain embodiments, R 8 is F. In certain embodiments, R 8 is Cl. In certain embodiments, R 8 is Br. In certain embodiments, R 8 is I. In certain embodiments, R 9 is H. In certain embodiments, R 9 is CH3. In certain embodiments, R 9 is CH 2 CH 3 . In certain embodiments, R 9 is CH 2 CH 2 CH 3 . In certain embodiments, R 9 is CH(CH3)2. In certain embodiments, R 9 is F.
  • R 9 -18- 55240579.2 Attorney Docket No.047162-7485WO1(02576) is Cl.
  • R 9 is Br.
  • R 9 is I.
  • R 10 is H.
  • R 10 is CH 3 .
  • R 10 is CH2CH3.
  • R 10 is CH2CH2CH3.
  • R 10 is CH(CH 3 ) 2 .
  • R 10 is F.
  • R 10 is Cl.
  • R 10 is Br.
  • R 10 is I.
  • R 11 is H. In certain embodiments, R 11 is CH 3 .
  • R 11 is CH2CH3. In certain embodiments, R 11 is CH2CH2CH3. In certain embodiments, R 11 is CH(CH 3 ) 2 . In certain embodiments, R 11 is F. In certain embodiments, R 11 is Cl. In certain embodiments, R 11 is Br. In certain embodiments, R 11 is I. In certain embodiments, R 12 is H. In certain embodiments, R 12 is CH 3 . In certain embodiments, R 12 is CH2CH3. In certain embodiments, R 12 is CH2CH2CH3. In certain embodiments, R 12 is CH(CH 3 ) 2 . In certain embodiments, R 12 is F. In certain embodiments, R 12 is Cl. In certain embodiments, R 12 is Br. In certain embodiments, R 12 is I.
  • R 13 is H. In certain embodiments, R 13 is CH 3 . In certain embodiments, R 13 is CH2CH3. In certain embodiments, R 13 is CH2CH2CH3. In certain embodiments, R 13 is CH(CH3)2. In certain embodiments, R 13 is F. In certain embodiments, R 13 is Cl. In certain embodiments, R 13 is Br. In certain embodiments, R 13 is I. In certain embodiments, X 4 is CR 13 , and R 5 and R 13 are not H. In certain embodiments, X 4 is N, and R 5 is not H. In certain embodiments, R 14 is H. In certain embodiments, R 14 is C1-C6 alkyl. In certain embodiments, R 15 is H.
  • R 15 is C 1 -C 6 alkyl.
  • Y is -(CH2)-G. In certain embodiments, Y is -(CH2)2-G. In certain embodiments, Y is -(CH 2 ) 3 -G. In certain embodiments, Y is -(CH 2 ) 4 -G. In certain embodiments, Y is -(CH2)5-G. In certain embodiments, Y is -(CH2)6-G. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 4. In certain embodiments, m is 5. In certain embodiments, m is 6.
  • G is -N(R 14 )(R 15 ). In certain embodiments, G is -OR 14 . In certain embodiments, G is . In certain embodiments, G is . In certain embodiments, G . In certain embodiments, G . In certain embodiments, . In certain -19- 55240579.2 Attorney Docket No.047162-7485WO1(02576) .In certain In certain embodiments, G is n is 0. In certain embodiments, n is 1. In certain n embodiments, n is 3. In certain embodiments, n is 4. In certain embodiments, the compound of formula (I) is a compound of formula (Ia): . In certain is a compound of formula (Ib): .
  • stereocenter can exist independently in either the (R) or (S) configuration.
  • compounds described herein are present in optically active or racemic forms.
  • the compounds described herein encompass racemic, optically-active, regioisomeric and stereoisomeric forms, or combinations thereof that possess the -22- 55240579.2 Attorney Docket No.047162-7485WO1(02576) therapeutically useful properties described herein.
  • Preparation of optically active forms is achieved in any suitable manner, including by way of non-limiting example, by resolution of the racemic form with recrystallization techniques, synthesis from optically-active starting materials, chiral synthesis, or chromatographic separation using a chiral stationary phase.
  • a mixture of one or more isomer is utilized as the therapeutic compound described herein.
  • compounds described herein contain one or more chiral centers.
  • These compounds are prepared by any means, including stereoselective synthesis, enantioselective synthesis and/or separation of a mixture of enantiomers and/ or diastereomers. Resolution of compounds and isomers thereof is achieved by any means including, by way of non-limiting example, chemical processes, enzymatic processes, fractional crystallization, distillation, and chromatography.
  • the methods and formulations described herein include the use of N-oxides (if appropriate), crystalline forms (also known as polymorphs), solvates, amorphous phases, and/or pharmaceutically acceptable salts of compounds having the structure of any compound(s) described herein, as well as metabolites and active metabolites of these compounds having the same type of activity.
  • Solvates include water, ether (e.g., tetrahydrofuran, methyl tert-butyl ether) or alcohol (e.g., ethanol) solvates, acetates and the like.
  • the compounds described herein exist in solvated forms with pharmaceutically acceptable solvents such as water, and ethanol.
  • the compounds described herein exist in unsolvated form.
  • the compound(s) described herein can exist as tautomers. All tautomers are included within the scope of the compounds presented herein.
  • sites on, for example, the aromatic ring portion of compound(s) described herein are susceptible to various metabolic reactions.
  • the appropriate substituent to decrease or eliminate the susceptibility of the aromatic ring to metabolic reactions is, by way of example only, a deuterium, a halogen, or an alkyl group.
  • Compounds described herein also include isotopically-labeled compounds wherein one or more atoms is replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes suitable for inclusion in the compounds described herein include and are not limited to 2 H, 3 H, 11 C, 13 C, 14 C, 36 Cl, 18 F, 123 I, 125 I, 13 N, 15 N, 15 O, 17 O, 18 O, 32 P, and 35 S.
  • isotopically-labeled compounds are useful in drug and/or substrate -23- 55240579.2 Attorney Docket No.047162-7485WO1(02576) tissue distribution studies.
  • substitution with heavier isotopes such as deuterium affords greater metabolic stability (for example, increased in vivo half-life or reduced dosage requirements).
  • substitution with positron emitting isotopes is useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
  • Isotopically-labeled compounds are prepared by any suitable method or by processes using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.
  • the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
  • an amine which can be an optionally substituted 2-amino pyridine or an optionally substituted 2-amino pyrimidine, each of which can be commercially available or prepared according to methods known in the art
  • an optionally substituted 2-hydroxy benzaldehyde which can be commercially available or prepared according to methods known in the art
  • an acid such as but not limited to formic acid, acetic acid, propionic acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like
  • a base such as but not limited -24- 55240579.2
  • a suitable solvent such as but not limited to methanol, ethanol, (iso)propanol, aceton
  • the imine can be purified from the reaction mixture or used as-is in the next reaction step.
  • the imine can then be contacted with an optionally substituted phenyl isocyanide, optionally substituted 2-pyridine isocyanide, optionally substituted 3-pyridine isocyanide, or optionally substituted 4-pyridine isocyanide (each of which can be commercially available or prepared according to methods known in the art) in a suitable solvent (such as but not limited to methanol, ethanol, (iso)propanol, acetonitrile, tetrahydrofuran, dimethylsulfoxide, chloroform, dichloromethane, and the like) in the optional presence of an acid (such as but not limited to formic acid, acetic acid, propionic acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like) or the optional presence of a base (such as but not limited to sodium hydroxide, potassium hydroxide, lithium hydrox
  • an amine an optionally substituted 2-amino pyridine or an optionally substituted 2-amino pyrimidine
  • an optionally substituted 2-hydroxy benzaldehyde an optionally substituted aromatic isocyanide
  • an optionally substituted aromatic isocyanide can be reacted in a single pot reaction so as to generate the desired product, or an intermediate, analogue, or protected from thereof.
  • an aniline in the optional presence of an acid (such as but not limited to formic acid, acetic acid, propionic acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, -25- 55240579.2 Attorney Docket No.047162-7485WO1(02576) phosphoric acid, and the like) and/or the optional presence of a base (such as but not limited to sodium hydroxide, potassium hydroxide, lithium hydroxide, triethylamine, Hunig’s base, pyridine, and the like) in a suitable solvent (such as but not limited to methanol, ethanol, (iso)propanol, acetonitrile, tetrahydrofuran, dimethylsulfoxide, chloroform, dichloromethane, and the like) to generate the corresponding alpha-anilino aromatic ketone, which can be reacted with a 2-amino pyridine or 2-amino pyrimidine in presence of an oxidant
  • the desired product can be isolated from the reaction mixture by (partial) removal of solvent from the reaction mixture, addition of water and/or any other suitable solvent to the reaction mixture, seeding, or any chemical/chromatographic method known in the art.
  • reactive functional groups such as hydroxyl, amino, imino, thio or carboxy groups, are protected in order to avoid their unwanted participation in reactions.
  • Protecting groups are used to block some or all of the reactive moieties and prevent such groups from participating in chemical reactions until the protective group is removed.
  • each protective group is removable by a different means.
  • Protective groups that are cleaved under totally disparate reaction conditions fulfill the requirement of differential removal.
  • protective groups are removed by acid, base, reducing conditions (such as, for example, hydrogenolysis), and/or oxidative conditions.
  • Groups such as trityl, dimethoxytrityl, acetal and t-butyldimethylsilyl are acid labile and are used to protect carboxy and hydroxy reactive moieties in the presence of amino groups protected -26- 55240579.2 Attorney Docket No.047162-7485WO1(02576) with Cbz groups, which are removable by hydrogenolysis, and Fmoc groups, which are base labile.
  • Carboxylic acid and hydroxy reactive moieties are blocked with base labile groups such as, but not limited to, methyl, ethyl, and acetyl, in the presence of amines that are blocked with acid labile groups, such as t-butyl carbamate, or with carbamates that are both acid and base stable but hydrolytically removable.
  • base labile groups such as, but not limited to, methyl, ethyl, and acetyl
  • carboxylic acid and hydroxy reactive moieties are blocked with hydrolytically removable protective groups such as the benzyl group, while amine groups capable of hydrogen bonding with acids are blocked with base labile groups such as Fmoc.
  • Carboxylic acid reactive moieties are protected by conversion to simple ester compounds as exemplified herein, which include conversion to alkyl esters, or are blocked with oxidatively-removable protective groups such as 2,4-dimethoxybenzyl, while co- existing amino groups are blocked with fluoride labile silyl carbamates. Allyl blocking groups are useful in the presence of acid- and base- protecting groups since the former are stable and are subsequently removed by metal or pi-acid catalysts. For example, an allyl-blocked carboxylic acid is deprotected with a palladium-catalyzed reaction in the presence of acid labile t-butyl carbamate or base-labile acetate amine protecting groups.
  • protecting group is a resin to which a compound or intermediate is attached. As long as the residue is attached to the resin, that functional group is blocked and does not react. Once released from the resin, the functional group is available to react.
  • blocking/protecting groups may be selected from: -27- 55240579.2 Attorney Docket No.047162-7485WO1(02576) creation of protecting groups and their removal are described in Greene & Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999, and Kocienski, Protective Groups, Thieme Verlag, New York, NY, 1994, which are incorporated herein by reference for such disclosure.
  • the pharmaceutical composition is formulated for ocular administration.
  • the disclosure provides a method of treating, ameliorating, and/or preventing AMD (such as, but not limited to, “dry” AMD) in a subject.
  • the method comprises administering of a subject (such as a subject in need thereof) a therapeutically effective amount of a compound contemplated herein.
  • the disclosure provides a method of treating, ameliorating, and/or preventing an anterior segment ocular disorder (such as but not limited to Fuchs endothelial corneal dystrophy (FECD), cataracts, ocular surface disease, glaucoma, and/or keratoconus).
  • an anterior segment ocular disorder such as but not limited to Fuchs endothelial corneal dystrophy (FECD), cataracts, ocular surface disease, glaucoma, and/or keratoconus.
  • the method comprises administering of a subject (such as a subject in need thereof) a therapeutically effective amount of a compound contemplated herein.
  • the disclosure provides a method of treating, ameliorating, and/or preventing blue light damage in a subject’s lens epithelial cell.
  • the method comprises administering of a subject (such as a subject in need thereof) a therapeutically effective amount of a compound contemplated herein.
  • a subject such as a subject in need thereof
  • a therapeutically effective amount of a compound contemplated herein a compound contemplated herein.
  • the atrophic or “dry” form of AMD is characterized by loss of RPE cells with loss of photoreceptors and the choriocapillaris. While the etiology of AMD is not fully understood, it is clear that risk factors such as advanced age, cigarette smoking, diet, and genetic differences (including but not limited to race) play a role in the development of the disease.
  • RPE cells are susceptible to oxidative stress and factors such as intense illumination into the eye or toxins in cigarettes contribute to the cumulative damage caused by this process. Moreover, antioxidant capacity decreases and the efficiency of reparative systems becomes impaired.
  • Age-related damage to -28- 55240579.2 Attorney Docket No.047162-7485WO1(02576) Bruch’s membrane (BM) caused by risk factors such as cigarette smoking is also associated with aberrant RPE cell behavior. These changes are a hallmark of AMD and result in retinal dysfunction and cell loss seen in atrophic AMD.
  • ROS reactive oxygen species
  • compounds of the disclosure prevent or minimize cell death caused by any cellular assault, which includes oxidative stress-related cellular assault or any other forms of cellular assault.
  • Tert-butyl hydroperoxide (TBHP) exposure has been demonstrated to disrupt junctional integrity of the RPE and cause lipid peroxidation of the membrane bilayer as well as the oxidation of glutathione, endoplasmic reticulum Ca 2+ release, increased intracellular calcium ([Ca 2+ ]), and increased mitochondrial inner membrane permeability.
  • UV-B light damage has been shown to target mitochondrial DNA damage and produce reactive oxygen species.
  • Treatment with one or more of the compounds of the disclosure promotes cell survival as measured by a cell viability assay when challenged with tert-butyl hydroperoxide causing oxidative stress-induced cellular dysfunction and death.
  • compounds of the disclosure can exhibit protective effects by enhancing mitochondrial respiration.
  • enhancing metabolic activity is a valid target for degenerative diseases such as AMD.
  • the compounds described herein act as selective agonists of GPX4 and/or prevent iron-dependent ferroptosis.
  • the activation of GPX4, and/or enhancement of GPX4’s activity, by the compounds described herein reduces oxidative stress and lipid peroxidation in the retina, protecting retinal cells and slowing down the progression of AMD.
  • the activation of GPX4 by the compounds described herein can serve therapeutic benefit with other diseases associated with ferroptosis and oxidative damage including acute kidney injury, cancer, cardiovascular diseases, neurodegenerative diseases, and/or hepatic diseases.
  • the regimen of administration may affect what constitutes an effective amount.
  • the therapeutic formulations may be administered to the subject either prior to or after the onset of a disease and/or disorder contemplated herein. Further, several divided dosages, as well as staggered dosages may be administered daily or sequentially, or the dose may be continuously infused, or may be a bolus injection. Further, the dosages of the therapeutic formulations may be proportionally increased or decreased as indicated by the exigencies of the therapeutic or prophylactic situation.
  • compositions of the present disclosure may be carried out using known procedures, at dosages and for periods of time effective to treat disease in the patient.
  • An effective amount of the therapeutic compound necessary to achieve a therapeutic effect may vary according to factors such as the state of the disease or disorder in the patient; the age, sex, and weight of the patient; and the ability of the therapeutic compound to treat a disease and/or disorder contemplated herein in the patient.
  • Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily, or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
  • a non-limiting example of an effective dose range for a therapeutic compound of the disclosure is from about 1 and 5,000 mg/kg of body weight/per day.
  • One of ordinary skill in the art would be able to study the relevant factors and make the determination regarding the effective amount of the therapeutic compound without undue experimentation.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of this disclosure may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • the selected dosage level depends upon a variety of factors including the activity of the particular compound employed, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds or materials used in combination with the compound, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well, known in the medical arts.
  • a medical doctor e.g., physician or veterinarian, having ordinary skill in the art may readily determine and prescribe the effective amount of the pharmaceutical composition required.
  • the physician or veterinarian could start doses of the compounds of -30- 55240579.2 Attorney Docket No.047162-7485WO1(02576) the disclosure employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the patients to be treated; each unit containing a predetermined quantity of therapeutic compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical vehicle.
  • the dosage unit forms of the disclosure are dictated by and directly dependent on (a) the unique characteristics of the therapeutic compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding/formulating such a therapeutic compound for the treatment of a disease and/or disorder contemplated herein in a patient.
  • the carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the compositions of the disclosure are administered to the patient in dosages that range from one to five times per day or more.
  • compositions of the disclosure are administered to the patient in range of dosages that include, but are not limited to, once every day, every two, days, every three days to once a week, once every two weeks, once every three weeks, once per month, once every 2 months, once every 3 months, and/or once every 1-12 weeks.
  • dosages include, but are not limited to, once every day, every two, days, every three days to once a week, once every two weeks, once every three weeks, once per month, once every 2 months, once every 3 months, and/or once every 1-12 weeks.
  • the frequency of administration of the various combination compositions of the disclosure varies from individual to individual depending on many factors including, but not limited to, age, disease or disorder to be treated, gender, overall health, and other factors.
  • the disclosure should not be construed to be limited to any particular dosage regime and the precise dosage and composition to be administered to any patient is determined by the attending physical taking all other factors about the patient into account.
  • Compounds of the disclosure for administration may be in the range of from about 1 ⁇ g to about 10,000 mg, about 20 ⁇ g to about 9,500 mg, about 40 ⁇ g to about 9,000 mg, about 75 ⁇ g to about 8,500 mg, about 150 ⁇ g to about 7,500 mg, about 200 ⁇ g to about 7,000 mg, about 350 ⁇ g to about 6,000 mg, about 500 ⁇ g to about 5,000 mg, about 750 ⁇ g to about 4,000 mg, about 1 mg to about 3,000 mg, about 10 mg to about 2,500 mg, about 20 mg to about 2,000 mg, about 25 mg to about 1,500 mg, about 30 mg to about 1,000 mg, about 40 -31- 55240579.2 Attorney Docket No.047162-7485WO1(02576) mg to about 900 mg, about 50 mg to about 800 mg, about 60 mg to about 750 mg, about 70 mg to about 600 mg, about 80 mg to about 500 mg, and any and all whole or partial increments therein between.
  • the dose of a compound of the disclosure is from about 1 mg and about 2,500 mg. In some embodiments, a dose of a compound of the disclosure used in compositions described herein is less than about 10,000 mg, or less than about 8,000 mg, or less than about 6,000 mg, or less than about 5,000 mg, or less than about 3,000 mg, or less than about 2,000 mg, or less than about 1,000 mg, or less than about 500 mg, or less than about 200 mg, or less than about 50 mg.
  • a dose of a second compound as described herein is less than about 1,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 400 mg, or less than about 300 mg, or less than about 200 mg, or less than about 100 mg, or less than about 50 mg, or less than about 40 mg, or less than about 30 mg, or less than about 25 mg, or less than about 20 mg, or less than about 15 mg, or less than about 10 mg, or less than about 5 mg, or less than about 2 mg, or less than about 1 mg, or less than about 0.5 mg, and any and all whole or partial increments thereof.
  • the compounds of the disclosure can be administered ophthalmically, for example via intraocular or periocular injection.
  • the compounds are administered in a gel or a pegylated material.
  • the compounds themselves are pegylated or conjugated to a long-lasting biological molecule.
  • the compounds are formulated for slow delivery to the eye, for example using contact lenses comprising a polymer that releases the drug slowly, using punctual plugs, and/or using any delivery methodology that is known in the art and compatible with the present compounds.
  • the present disclosure is directed to a packaged pharmaceutical composition
  • a packaged pharmaceutical composition comprising a container holding a therapeutically effective amount of a compound of the disclosure, alone or in combination with a second pharmaceutical agent; and instructions for using the compound to treat, prevent, or reduce one or more symptoms of a disease and/or disorder contemplated herein in a patient.
  • Formulations may be employed in admixtures with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for oral, parenteral, nasal, intravenous, subcutaneous, enteral, or any other suitable mode of administration, known to the art.
  • the pharmaceutical preparations may be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, -32- 55240579.2 Attorney Docket No.047162-7485WO1(02576) emulsifiers, salts for influencing osmotic pressure buffers, coloring, flavoring and/or aromatic substances and the like. They may also be combined where desired with other active agents, e.g., other analgesic agents.
  • Routes of administration of any of the compositions of the disclosure include oral, nasal, rectal, intravaginal, parenteral, buccal, sublingual, intraocular, or topical.
  • the compounds for use in the disclosure may be formulated for administration by any suitable route, such as for oral or parenteral, for example, transdermal, transmucosal (e.g., sublingual, lingual, (trans)buccal, (trans)urethral, vaginal (e.g., trans- and perivaginally), (intra)nasal and (trans)rectal), intravesical, intrapulmonary, intraduodenal, intragastric, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, topical administration, and ophthalmic(including but not limited to topical, subconjunctival, subTenon’s, suprachoroidal, intravitreal, or subretinal),
  • suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders
  • compositions and compositions that would be useful in the present disclosure are not limited to the particular formulations and compositions that are described herein.
  • Oral Administration For oral application, particularly suitable are tablets, dragees, liquids, drops, suppositories, or capsules, caplets and gelcaps.
  • the compositions intended for oral use may be prepared according to any method known in the art and such compositions may contain one or more agents selected from the group consisting of inert, non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets.
  • excipients include, for example an inert diluent such as lactose; granulating and disintegrating agents such as cornstarch; binding agents such as starch; and lubricating agents such as magnesium stearate.
  • the tablets may be uncoated, or they may be coated by known techniques for elegance or to delay the release of the active ingredients.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert diluent.
  • the present disclosure also includes a multi-layer tablet comprising a layer providing for the delayed release of one or more compounds of the disclosure, and a further layer providing for the immediate release of a medication for treatment of certain diseases or -33- 55240579.2 Attorney Docket No.047162-7485WO1(02576) disorders.
  • a gastric insoluble composition may be obtained in which the active ingredient is entrapped, ensuring its delayed release.
  • Parenteral Administration For parenteral administration, the compounds of the disclosure may be formulated for injection or infusion, for example, intravenous, intramuscular, or subcutaneous injection or infusion, or for administration in a bolus dose and/or continuous infusion.
  • Suspensions, solutions or emulsions in an oily or aqueous vehicle, optionally containing other formulatory agents such as suspending, stabilizing and/or dispersing agents may be used.
  • Ophthalmological Administrations The disclosure contemplates administering to the eye the compounds useful within the disclosure. Any ophthalmological formulations can be useful within the present disclosure, as well as they allow for application of the compounds useful within the disclosure to the eye.
  • the compositions of the disclosure may be in the form of a suspension or solution can then be stirred for a period of time (for example, 1 hour) after which the pH is adjusted to about 5-8, preferably about 6.5-7.5.
  • the suspension or solution can be allowed to stir for up to about 24 hours after which it is used directly, diluted with buffer to a desired concentration, and/or lyophilized to provide a powder for reconstitution.
  • the lyophilized powder can be suspended in an amount of water that will not dissolve the powder completely but will provide a fine suspension.
  • This suspension can then be further formulated with a thickening agent to improve adherence to the eye.
  • Thickening agents include, but are not limited to, carboxymethylcellulose, hydroxymethylcellulose (for example, at a concentration of about 0.05-5%), or other approved agents.
  • the thickening agent includes hydroxymethylcellulose.
  • the thickening agent includes carboxymethylcellulose.
  • the compound is in a dispersion formulation.
  • the dispersion formulation is aqueous. In some embodiments, the dispersion formulation is a suspension, colloid, or solution. In some embodiments, the dispersion formulation is a solid. In some embodiments, the dispersion formulation comprises a thickening agent. In some embodiments, the dispersion formulation comprises hydroxymethylcellulose.
  • the dispersion formulation comprises microcrystalline cellulose, methylcellulose, ethylcellulose, carboxymethylcellulose, ethylhydroxyethylcellulose, ethylmethylcellulose, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, -34- 55240579.2 Attorney Docket No.047162-7485WO1(02576) hydroxymethylcellulose. Additional Administration Forms Additional dosage forms of this disclosure include dosage forms as described in U.S. Patents Nos.6,340,475; 6,488,962; 6,451,808; 5,972,389; 5,582,837; and 5,007,790.
  • Additional dosage forms of this disclosure also include dosage forms as described in U.S. Patent Applications Nos.20030147952; 20030104062; 20030104053; 20030044466; 20030039688; and 20020051820. Additional dosage forms of this disclosure also include dosage forms as described in PCT Applications Nos. WO 03/35041; WO 03/35040; WO 03/35029; WO 03/35177; WO 03/35039; WO 02/96404; WO 02/32416; WO 01/97783; WO 01/56544; WO 01/32217; WO 98/55107; WO 98/11879; WO 97/47285; WO 93/18755; and WO 90/11757.
  • the formulations of the present disclosure may be, but are not limited to, short-term, rapid-offset, as well as controlled, for example, sustained release, delayed release and pulsatile release formulations.
  • sustained release is used in its conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, and that may, although not necessarily, result in substantially constant blood levels of a drug over an extended time period. The period of time may be as long as a month or more and should be a release which is longer than the same amount of agent administered in bolus form.
  • the compounds may be formulated with a suitable polymer or hydrophobic material which provides sustained release properties to the compounds.
  • the compounds for use within the methods of the disclosure may be administered in the form of microparticles, for example, by injection or in the form of wafers or discs by implantation.
  • compounds of the disclosure are administered to a patient, alone or in combination with another pharmaceutical agent, using a sustained release formulation.
  • delayed release is used herein in its conventional sense to refer to a drug formulation that provides for an initial release of the drug after some delay following drug administration and that mat, although not necessarily, includes a delay of from about 10 minutes up to about 12 hours.
  • pulsatile release is used herein in its conventional sense to refer to a drug formulation that provides release of the drug in such a way as to produce pulsed plasma profiles of the drug after drug administration.
  • immediate release is used in its conventional sense to refer to a drug formulation that provides for release of the drug immediately after drug administration.
  • short-term refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes and any or all whole or partial increments thereof after drug administration after drug administration.
  • rapid-offset refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes, and any and all whole or partial increments thereof after drug administration.
  • Dosing The therapeutically effective amount or dose of a compound of the present disclosure depends on the age, sex and weight of the patient, the current medical condition of the patient and the progression of AMD in the patient being treated. The skilled artisan is able to determine appropriate dosages depending on these and other factors.
  • a suitable dose of a compound of the present disclosure may be in the range of from about 0.01 mg to about 5,000 mg per day, such as from about 0.1 mg to about 1,000 mg, for example, from about 1 mg to about 500 mg, such as about 5 mg to about 250 mg per day.
  • the dose may be administered in a single dosage or in multiple dosages, for example from 1 to 4 or more times per day. When multiple dosages are used, the amount of each dosage may be the same or different.
  • a dose of 1 mg per day may be administered as two 0.5 mg doses, with about a 12-hour interval between doses. It is understood that the amount of compound dosed per day may be administered, in non-limiting examples, every day, every other day, every 2 days, every 3 days, every 4 days, or every 5 days.
  • a 5 mg per day dose may be initiated on Monday with a first subsequent 5 mg per day dose administered on Wednesday, a second subsequent 5 mg per day dose administered on Friday, and so on.
  • the administration of the inhibitor of the disclosure is optionally given continuously; alternatively, the dose of drug being administered is temporarily reduced or temporarily suspended for a certain length of time (i.e., a “drug holiday”).
  • the length of the drug holiday optionally varies between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 -36- 55240579.2 Attorney Docket No.047162-7485WO1(02576) days, 320 days, 350 days, or 365 days.
  • the dose reduction during a drug holiday includes from 10%-100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
  • a maintenance dose is administered if necessary.
  • the dosage or the frequency of administration, or both is reduced, as a function of the viral load, to a level at which the improved disease is retained.
  • patients require intermittent treatment on a long-term basis upon any recurrence of symptoms and/or infection.
  • the compounds for use in the method of the disclosure may be formulated in unit dosage form.
  • unit dosage form refers to physically discrete units suitable as unitary dosage for patients undergoing treatment, with each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, optionally in association with a suitable pharmaceutical carrier.
  • the unit dosage form may be for a single daily dose or one of multiple daily doses (e.g., about 1 to 4 or more times per day). When multiple daily doses are used, the unit dosage form may be the same or different for each dose. Toxicity and therapeutic efficacy of such therapeutic regimens are optionally determined in cell cultures or experimental animals, including, but not limited to, the determination of the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between the toxic and therapeutic effects is the therapeutic index, which is expressed as the ratio between LD 50 and ED50.
  • the data obtained from cell culture assays and animal studies are optionally used in formulating a range of dosage for use in human.
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with minimal toxicity.
  • the dosage optionally varies within this range depending upon the dosage form employed and the route of administration utilized.
  • reaction conditions including but not limited to reaction times, reaction size/volume, and experimental reagents, such as solvents, catalysts, pressures, atmospheric conditions, e.g., nitrogen atmosphere, and reducing/oxidizing agents, with art- recognized alternatives and using no more than routine experimentation, are within the scope -37- 55240579.2 Attorney Docket No.047162-7485WO1(02576) of the present application. It is to be understood that wherever values and ranges are provided herein, all values and ranges encompassed by these values and ranges, are meant to be encompassed within the scope of the present disclosure.
  • RPE Human retinal pigment epithelial
  • ARPE-19 Human retinal pigment epithelial cells obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Thermo Fisher Scientific, Waltham, MA) containing 10% fetal bovine serum (FBS), 100 IU/mL penicillin, 100 ⁇ g/mL streptomycin, 100 ⁇ g/mL gentamicin, and 2.5 ⁇ g/mL amphotericin B (Thermo Fisher Scientific).
  • DMEM Dulbecco’s modified Eagle’s medium
  • FBS fetal bovine serum
  • ARPE-19 cells were plated in 96-well plates for 24 hours in DMEM supplemented with FBS and antibiotics. ARPE-19 cells were preincubated with either ciclopirox olamine (Sigma), compound C325-0414 (Chemical Diversity, San Diego, CA), -38- 55240579.2 Attorney Docket No.047162-7485WO1(02576) compound 434 (Chemical Diversity) or no compound for 24 hours and then exposed to varying concentrations of tert-butyl hydroperoxide (TBHP; Sigma-Aldrich, St. Louis, MO) the next day for 24 hours.
  • TBHP tert-butyl hydroperoxide
  • ARPE-19 cells were grown on 24-well Transwell ® permeable supports (Corning, Inc.) in 12-well plates or flat bottom 24-well plates for 6–8 weeks to allow the ECM to form. ARPE-19 cells were then removed by the addition of 20 mM ammonium hydroxide buffer for 20 min, and the ECM was washed with phosphate buffered saline (PBS). PBS was removed from the RPE-ECM plates and dried. Subsequently, 100 mM sodium nitrite was added to the ECM and incubated at 37°C for 7 days. Plates were then washed with PBS and incubated with PBS for 4 hours.
  • PBS phosphate buffered saline
  • the compound was first preincubated with recombinant GPX4 (item no.26906; Cayman Chemical, Ann Arbor, MI) in the assay buffer of the glutathione peroxidase assay (item no.703102; Cayman Chemical). Each compound was dissolved in DMSO at a final concentration of 5%, which did not perturb the assay. Fluorescence signals were recorded on a plate reader (Synergy, BioTek). Control experiments were also conducted to confirm that the compounds were not glutathione reductase activators or inhibitors.
  • SPR Surface plasmon resonance
  • GPX4 ligands -40- 55240579.2 Attorney Docket No.047162-7485WO1(02576) DH476A (FIG.7), DH404-AF (FIG.8), and DH464 (FIG.9) were tested using Cayman GPX4 to validate the binding of compounds to GPX4. Results show good binding of each compound to GPX4. DH464 shows the highest affinity among the group of compounds tested.
  • Molsoft software Molsoft, LLC, San Diego, CA.
  • PDB structure 6ELW was loaded into ICM-chemist pro and ICM Pocket Finder run to identify the major surface binding site.
  • Example 1 Chemical Synthesis Synthesis of 4-Bromo-2-(7-((dimethylamino)methyl)-3-((2,6- dimethylphenyl)amino)imidazo-[1,2-a]pyridin-2-yl)phenol (DH464A).
  • Imidazopyrimidines have added polar surface area versus imidazopyridine on the molecular surface versus and thus can increase solubility in aqueous solutions. Increased aqueous solubility may provide other additional benefits when administered to subjects for therapeutic purposes.
  • Example 2 Protection of human retinal pigment epithelial (RPE) cells from oxidative stress-induced cell death As illustrated in FIG.1, a compound of the disclosure (DH464) was found to protect human retinal pigment epithelial (RPE) cells from oxidative stress-induced cell death.
  • Embodiment 1 A compound of formula (I): from the group consisting of H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , CH(CH 3 ) 2 , F, Cl, Br, I, and Y, with the proviso that at least one of R 1 (if present), R 2 , R 3 , and R 4 is Y; Y is -(CH2)m-G; m is 1, 2, 3, 4, 5, or 6; -44- 55240579.2 Attorney Docket No.047162-7485WO1(02576) G is selected from the group consisting , ; n is 0, one of applies: X 2 is CR 7 , X 3 is CR 8 , and X 4 is CR 13 , or X 2 is N, X 3 is CR 8 , and X 4 is CR 13 , or
  • Embodiment 2 The compound of embodiment 1, wherein X 1 is N.
  • Embodiment 3 The compound of embodiment 1, wherein X 1 is CR 1 .
  • Embodiment 4 The compound of any one of embodiments 1-3, wherein X 2 is CR 7 , X 3 is CR 8 , and X 4 is CR 13 .
  • Embodiment 5 The compound of any one of embodiments 1-3, wherein X 2 is N, X 3 is CR 8 , and X 4 is CR 13 .
  • Embodiment 6 The compound of any one of embodiments 1-3, wherein X 2 is CR 7 , X 3 is N, and X 4 is CR 13 .
  • Embodiment 7 The compound of any one of embodiments 1-3, wherein X 2 is CR 7 , X 3 is CR 8 , and X 4 is N.
  • Embodiment 8 The compound of any one of embodiments 1-7, wherein R 10 is Br and/or wherein R 11 is Br or F.
  • Embodiment 9 The compound of any one of embodiments 1-8, wherein R 5 , R 6 , R 7 , and R 8 (if present) are H.
  • Embodiment 10 The compound of any one of embodiments 1-9, which is: -45- 55240579.2 Attorney Docket No.047162-7485WO1(02576) .
  • Embodiment 16 A method of treating, ameliorating, and/or preventing an anterior segment ocular disorder in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of embodiments 1-12.
  • Embodiment 17 The method of embodiment 16, wherein the disorder comprises at least one selected from the group consisting of Fuchs Endothelial Corneal Dystrophy, cataracts, ocular surface disease, glaucoma, and keratoconus.
  • Embodiment 18 The method of treating, ameliorating, and/or preventing cell death, and/or promoting cell viability, in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of embodiments 1-12.
  • Embodiment 19 The method of embodiment 18, wherein the cell death comprises oxidative stress-induced cell death.
  • Embodiment 20 The method of embodiment 18, wherein the cell comprises a lens epithelial cell.
  • Embodiment 21 The method of embodiment 18, wherein the cell death is associated with at least one disease selected from the group consisting of heart failure and other cardiovascular; pulmonary fibrosis, kidney disease, diabetic macular edema and retinopathies, neurodegeneration, mitochondrial myopathy, Barth’s syndrome, and liver disease.
  • Embodiment 22 A method of treating, ameliorating, and/or preventing blue light damage in a subject’s lens epithelial cell, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of embodiments 1-12
  • Embodiment 23 The method of any one of embodiments 13-22, wherein the compound is formulated in a pharmaceutically acceptable composition further comprising at least one pharmaceutically acceptable excipient.
  • Embodiment 24 The method of any of embodiments 13-20 and 22-23, wherein the compound is administered ocularly to the subject.
  • Embodiment 25 The method of any one of embodiments 13-24, wherein the compound is one of the , -48- 55240579.2 Attorney Docket No.047162-7485WO1(02576) , of embodiments 1-12 and at least one pharmaceutically acceptable excipient.
  • Embodiment 27 The pharmaceutical composition of embodiment 26, which is formulated for ocular administration.
  • Embodiment 28 The pharmaceutical composition of any one of embodiments 26-27, which has pH of about 5-8.
  • Embodiment 29 The pharmaceutical composition of any one of embodiments 26-28, which is lyophilized.
  • Embodiment 30 The pharmaceutical composition of any one of embodiments 26-29, which further comprises a thickening agent.
  • Embodiment 31 The pharmaceutical composition of any one of claims 26-30, wherein the pharmaceutical composition is a solid formulation.
  • Embodiment 32 The pharmaceutical composition of 31, wherein the solid formulation comprises hydroxymethylcellulose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La divulgation concerne une méthode de traitement, d'atténuation et/ou de prévention de dégénérescences rétiniennes, telles que, mais de façon non limitative, des troubles du segment antérieur de l'oeil et/ou une dégénérescence maculaire liée à l'âge (DMLA), chez un sujet. Dans certains modes de réalisation, le procédé comprend l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé de l'invention. Dans certains modes de réalisation, le composé de l'invention empêche et/ou réduit à un minimum l'attaque cellulaire, tel que l'attaque cellulaire liée au stress oxydatif, et/ou favorise la viabilité cellulaire.
PCT/US2025/020532 2024-03-19 2025-03-19 Imidazopyridines et imidazopyrimidines, et leurs procédés d'utilisation Pending WO2025199211A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463567289P 2024-03-19 2024-03-19
US63/567,289 2024-03-19

Publications (1)

Publication Number Publication Date
WO2025199211A1 true WO2025199211A1 (fr) 2025-09-25

Family

ID=97140134

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/020532 Pending WO2025199211A1 (fr) 2024-03-19 2025-03-19 Imidazopyridines et imidazopyrimidines, et leurs procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2025199211A1 (fr)

Similar Documents

Publication Publication Date Title
JP6602802B2 (ja) Ｓｓａｏの置換３−ハロアリルアミン阻害剤およびその使用
US10196376B2 (en) Hepatitis B antiviral agents
RU2767460C2 (ru) Соединения, композиции и способы для повышения активности cftr
US20250282772A1 (en) Compounds as glp-1r agonists
EP2943467B1 (fr) Dérivés de benzylidèneguanidine et leur utilisation thérapeutique pour le traitement de maladies liées au repliement anormal des protéines
CA2952069C (fr) Agents anti-cicatrices formes de petites molecules
US20210353571A1 (en) Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof
US20250144115A1 (en) Amide compound as potassium channel regulator, and preparation therefor and use thereof
US20090227562A1 (en) Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
WO2025199211A1 (fr) Imidazopyridines et imidazopyrimidines, et leurs procédés d'utilisation
CN105801464A (zh) 吡咯酰胺类化合物及其制备方法与用途
US20250288588A1 (en) Substituted imidazopyridines and imidazopyrimidines, and use of same for treating, ameliorating, and/or preventing retinal degeneration
WO2021155781A1 (fr) Composé de benzène sulfonamide contenant un hétérocycle à cinq chaînons, son procédé de préparation et son utilisation
JP2025528475A (ja) リシルオキシダーゼの新規選択的阻害剤
WO2024091659A1 (fr) Cyclodextrines modifiées et leurs utilisations ophtalmiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25774420

Country of ref document: EP

Kind code of ref document: A1